Rilotumumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Anti-HGF monoclonal antibody AMG 102 binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met. c-Met (HGF receptor or HGFR), a receptor tyrosine kinase overexpressed or mutated in a variety of epithelial cancer cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.

**Synonyms:** - AMG 102 - AMG 102 - AMG-102 - AMG102 - Anti-HGF Monoclonal Antibody AMG 102 - Fully Human Anti-HGF Monoclonal Antibody AMG 102 - RILOTUMUMAB - anti-HGF monoclonal antibody AMG 102